Edelweiss Mutual Fund
Up to one year: absolute. Longer: annualised. Category = median of Index Funds direct-plan Growth funds.
| Period | This fund | Category median | Rank in category |
|---|---|---|---|
| 1 month | -3.20% | -5.37% | — |
| 3 months | +2.18% | -4.10% | — |
| 6 months | +15.01% | +3.59% | — |
| 1 year | +17.80% | +1.93% | #6 of 318 Top 2% |
| 3 years | +18.52% | +7.42% | #5 of 164 Top 4% |
| 5 years | +13.57% | +6.41% | #5 of 42 Top 12% |
| 10 years | — | +10.93% | — |
| Since launch of NAV data | +16.10% | — | — |
| Window | High | Low |
|---|---|---|
| 1 month | 25.0984 | 24.1477 |
| 3 months | 25.2035 | 23.6332 |
| 6 months | 25.2035 | 20.6897 |
| 1 year | 25.2035 | 20.4987 |
A period is a dash when the fund has not existed that long or its NAV history has a hole at the start date — never a partial figure.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | YTD | |
|---|---|---|---|---|---|---|---|
| This fund | — | +18.78% | -4.75% | +25.11% | +29.57% | +5.48% | +12.67% |
| Category median | +15.51% | +25.21% | +3.61% | +21.04% | +9.93% | +7.90% | -2.53% |
Twenty checks of five points each: performance, portfolio, operations, and risk against reward. Only checks we have data for are counted.
Risk-free rate 6.06% (3-year annualised return of the NSE 1-day (overnight) rate index). This category has no reference index in our data, so benchmark-relative ratios are not shown.
| Ratio | This fund | Category median | Against category |
|---|---|---|---|
| Sharpe ratio | 1.06 | 0.46 | Better |
| Sortino ratio | 1.50 | 0.65 | Better |
| Standard deviation | 11.75% | 13.27% | Better |
| Maximum drawdown | -12.15% | -15.52% | Better |
| Beta | — | 1.00 | — |
| R-squared | — | 100.0% | — |
| Jensen's alpha | — | -0.41% | — |
| Treynor ratio | — | 2.09 | — |
| Information ratio | — | -3.62 | — |
| Upside capture | — | 99.6% | — |
| Downside capture | — | 100.0% | — |
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Equity | 99.80% |
| Cash & Equivalents | 0.20% |
Click a sector to filter the holdings below (holdings map to our sector list where the company is known).
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 11.30% | -0.61 pp | 146.5 |
| ELI LILLY & CO | — | 6.43% | 0.73 pp | — |
| Divi's Laboratories Ltd | Healthcare | 6.07% | 0.74 pp | 83.9 |
| Apollo Hospitals Enterprise Limited | Healthcare | 5.69% | 0.04 pp | 74.7 |
| Max Healthcare Institute Limited | Healthcare | 4.89% | -0.41 pp | 126.0 |
| Cipla Ltd | Healthcare | 4.69% | -0.39 pp | 35.4 |
| Torrent Pharmaceuticals Ltd | Healthcare | 4.61% | 1.21 pp | 78.2 |
| JOHNSON & JOHNSON | — | 4.30% | 0.13 pp | — |
| Laurus Labs Ltd | Healthcare | 4.02% | 1.37 pp | 122.5 |
| Dr. Reddy's Laboratories Limited | Healthcare | 3.63% | -1.30 pp | 154.7 |
| Lupin Limited | Healthcare | 3.48% | -0.49 pp | 13.3 |
| ABBVIE INC | — | 3.09% | 0.28 pp | — |
| Fortis Healthcare Ltd | Healthcare | 2.93% | -0.18 pp | 257.5 |
| Aurobindo Pharma Ltd | Healthcare | 2.61% | 0.11 pp | 37.4 |
| MERCK & CO.INC | — | 2.24% | 0.20 pp | — |
| NOVARTIS AG - SPONSORED ADR | — | 1.99% | -0.12 pp | — |
| Glenmark Pharmaceuticals Limited | Healthcare | 1.99% | -0.57 pp | 321.6 |
| Biocon Limited | Healthcare | 1.74% | 0.25 pp | 597.3 |
| Mankind Pharma Ltd | Healthcare | 1.61% | -0.30 pp | 47.4 |
| IPCA Laboratories Ltd | Healthcare | 1.54% | 0.07 pp | 39.3 |
| Alkem Laboratories Ltd | Healthcare | 1.52% | -0.25 pp | 28.9 |
| THERMO FISHER SCIENTIFIC INC | — | 1.49% | 0.14 pp | — |
| AMGEN INC | — | 1.45% | 0.04 pp | — |
| Zydus Lifesciences Ltd | Healthcare | 1.32% | 0.09 pp | 33.3 |
| ABBOTT LABORATORIES | — | 1.28% | 0.10 pp | — |
| Aster Dm Quality Care Ltd | Healthcare | 1.21% | 0.09 pp | 207.5 |
| Gland Pharma Ltd | Healthcare | 1.17% | 0.28 pp | 34.3 |
| GILEAD SCIENCES INC | — | 1.13% | -0.10 pp | — |
| NOVO-NORDISK A/S | — | 1.06% | 0.03 pp | — |
| Ajanta Pharma Limited | Healthcare | 0.96% | 0.11 pp | 44.9 |
| INTUITIVE SURGICAL INC | — | 0.87% | -0.36 pp | — |
| DANAHER CORP | — | 0.87% | 0.01 pp | — |
| VERTEX PHARMACEUTICALS INC | — | 0.84% | 0.03 pp | — |
| STRYKER CORP | — | 0.78% | -0.04 pp | — |
| Narayana Hrudayalaya Limited | Healthcare | 0.78% | -0.08 pp | 64.4 |
| MEDTRONIC PLC | — | 0.76% | -0.02 pp | — |
| Global Health Ltd | Healthcare | 0.71% | 0.10 pp | 76.2 |
| GlaxoSmithKline Pharmaceuticals Ltd | Healthcare | 0.64% | -0.04 pp | 44.3 |
| REGENERON PHARMACEUTICALS INC | — | 0.55% | -0.01 pp | — |
| Anthem Biosciences Limited | Healthcare | 0.44% | 0.44 pp | 77.2 |
| BECTON DICKINSON AND CO | — | 0.33% | 0.01 pp | — |
| IQVIA HOLDINGS INC | — | 0.28% | 0.08 pp | — |
| AGILENT TECHNOLOGIES INC | — | 0.27% | 0.03 pp | — |
| WATERS CORP | — | 0.26% | 0.17 pp | — |
| Net Receivables/(Payables) | — | 0.15% | 0.12 pp | — |
| Clearing Corporation of India Ltd. | — | 0.05% | -0.22 pp | — |
Expense ratio by month: Oct 25 0.52% · Nov 25 0.52% · Dec 25 0.52% · Jan 26 0.52% · Feb 26 0.52% · Mar 26 0.52% · Apr 26 0.51% · May 26 0.51% · Jun 26 0.52% · Jul 26 0.54% · Aug 26 0.56% · Sep 26 0.55%
Nil
The Scheme will invest in stocks comprising of the MSCI India Domestic IMI and World Healthcare Select Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.; However, there is no assurance that the investment objective of the Scheme will be realized and the Scheme does not assure or guarantee any returns.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
